Brokers Offer Predictions for Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Investment analysts at Chardan Capital cut their FY2025 earnings per share (EPS) estimates for Korro Bio in a report issued on Wednesday, May 14th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($10.00) for the year, down from their prior forecast of ($9.68). Chardan Capital has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. Chardan Capital also issued estimates for Korro Bio's FY2026 earnings at ($7.83) EPS.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada cut their target price on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research note on Wednesday, March 19th. Oppenheimer dropped their price target on Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. HC Wainwright reduced their price objective on Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald upgraded Korro Bio to a "strong-buy" rating in a report on Tuesday, April 29th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $102.43.

Korro Bio Stock Performance

KRRO opened at $15.11 on Monday. The firm has a market cap of $141.90 million, a price-to-earnings ratio of -1.60 and a beta of 2.66. Korro Bio has a twelve month low of $11.13 and a twelve month high of $98.00. The firm's 50-day simple moving average is $17.12 and its 200-day simple moving average is $32.41.

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, beating analysts' consensus estimates of ($2.60) by $0.11. The business had revenue of $2.55 million during the quarter, compared to the consensus estimate of $0.13 million.

Hedge Funds Weigh In On Korro Bio

Several large investors have recently bought and sold shares of the business. Deep Track Capital LP increased its stake in shares of Korro Bio by 2.9% in the 4th quarter. Deep Track Capital LP now owns 874,614 shares of the company's stock valued at $33,297,000 after acquiring an additional 24,614 shares during the last quarter. Alliancebernstein L.P. acquired a new position in Korro Bio during the fourth quarter valued at approximately $26,870,000. Driehaus Capital Management LLC increased its stake in Korro Bio by 17.7% in the first quarter. Driehaus Capital Management LLC now owns 582,449 shares of the company's stock valued at $10,140,000 after purchasing an additional 87,544 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Korro Bio by 11.0% in the fourth quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company's stock worth $18,806,000 after purchasing an additional 49,147 shares during the period. Finally, Cormorant Asset Management LP acquired a new stake in Korro Bio in the first quarter worth $6,621,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.